Filing Flows › Foghorn Therapeutics (FHTX) › Q1 2026 › vs Q1 2025
Foghorn Therapeutics (FHTX) Q1 2026 vs Q1 2025 (year over year)
Foghorn Therapeutics's revenue fell $2.7M (-45%) from $6.0M in Q1 2025 to $3.3M in Q1 2026.
Foghorn Therapeutics, Q1 2026: revenue $3.3M (-45% year over year), operating margin -660.3%, net loss $19.9M, operating cash flow −$25.3M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $3.3M | $6.0M | −$2.7M | -45% |
| Other income, net | $1.7M | $4.1M | −$2.4M | -58% |
| Net loss | $19.9M | $18.8M | $1.0M | +6% |
| Costs & expenses | $24.8M | $28.9M | −$4.0M | -14% |
| Operating costs | $24.8M | $28.9M | −$4.0M | -14% |
| Research & development | $18.3M | $21.6M | −$3.4M | -16% |
| General & admin | $6.6M | $7.2M | −$658K | -9% |
| Operating cash sources | $27.9M | $27.5M | $400K | +1% |
| Depreciation & amortization | $238K | $827K | −$589K | -71% |
| Share-based compensation | $2.4M | $2.7M | −$309K | -11% |
| Cash used in operations | $25.3M | $24.0M | $1.3M | +5% |
| Net loss absorbed | $19.9M | $18.8M | $1.0M | +6% |
| Working capital & other | $8.0M | $8.7M | −$641K | -7% |
Questions
How much did Foghorn Therapeutics's revenue grow year over year in Q1 2026?
Foghorn Therapeutics's revenue fell $2.7M (-45%) from $6.0M in Q1 2025 to $3.3M in Q1 2026.